Zentalis Pharmaceuticals, Inc. 8-K

What Happened Zentalis Pharmaceuticals, Inc. filed an 8-K disclosing the results of its 2026 Annual Meeting of Stockholders held June 16, 2026. A total of 49,453,766 shares were present or represented by proxy (about 69.47% of outstanding shares as of the April 20, 2026 record date). David Johnson and Jan Skvarka, Ph.D. were elected as Class III directors, and stockholders ratified Ernst & Young LLP as the company’s independent registered public accounting firm and approved, on an advisory basis, the compensation of the company’s named executive officers.

Key Details

• Shares present/represented: 49,453,766 (≈69.47% of outstanding as of April 20, 2026).
• Director elections:
  • David Johnson — For: 20,711,869; Withheld: 12,215,784; Broker non‑votes: 16,526,113.
  • Jan Skvarka, Ph.D. — For: 23,497,184; Withheld: 9,430,469; Broker non‑votes: 16,526,113.
• Auditor ratification (Item 2): For: 49,321,951; Against: 13,557; Abstain: 118,258.
• Advisory vote on executive compensation (Item 3): For: 21,949,844; Against: 10,930,673; Abstain: 47,136; Broker non‑votes: 16,526,113.

Why It Matters The filing confirms the company’s governance outcomes from the annual meeting: two directors were elected to serve through the 2029 annual meeting, the company’s auditor was ratified for fiscal 2026, and shareholders gave advisory approval to executive pay. Voter turnout was strong (about 69.5%), and the reported vote counts give investors clear, factual insight into shareholder support levels for board composition, the auditor, and compensation practices.